Иммунопрофилактика респираторно-синцитиальной вирусной инфекции у младенцев с бронхолегочной дисплазией (часть I)

Immunoprophylaxis of respiratory syncytial virus infection in infants with bronchopulmonary dysplasia (part I)

The review contains information about contribution of respirtory syncytial virus (RSV) into development of acute states of bronchopulmonary dysplasia (BPD). An innovative highly-effectively method of prevention of RSV- infection in infants with BPD is described by means of monoclonal antibody drug - рalivizumab. General data on a new class of immunostimulating therapy - humanized target-specific monoclonal antibody are presented. Immunobyological characteristics, mechanism of action, farmacokinetics and effectiveness of palivizumab in patients with BPD are also described.